Audited Results for the Year Ended 30 April 2008 for Scancell Limited
The Directors of Scancell Holdings Plc are pleased to announce the audited results for Scancell Limited for the year ended 30 April 2008.
In the last financial year we have consolidated our position in relation to the science and the finances of the Company.
In November, I was elected Non-Executive Chairman and brought my considerable experience in listed companies to the board. A decision was made at the beginning of 2008 to list the Company on the PLUS Market (www.PLUSmarketsgroup.com) and successfully achieved on the 24th of September 2008.This has attracted new finance to progress our lead product SCIB1 into the clinic and continue the development of the ImmunoBody platform. A decision was made by the directors that they are not paying a dividend for the period.
We look forward to updating shareholders with developments over the coming months.
It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia
Mon, 08 Apr 2019 08:20:00
The US patent covers Modi-1, while the European patent relates to a monoclonal antibody called FG88
Wed, 20 Mar 2019 07:55:00
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise
Tue, 12 Feb 2019 15:07:00
Sign up to our newsletter to stay up to date with Scancell